MX2024013133A - Metodo y composicion para prevenir o tratar la miopia - Google Patents

Metodo y composicion para prevenir o tratar la miopia

Info

Publication number
MX2024013133A
MX2024013133A MX2024013133A MX2024013133A MX2024013133A MX 2024013133 A MX2024013133 A MX 2024013133A MX 2024013133 A MX2024013133 A MX 2024013133A MX 2024013133 A MX2024013133 A MX 2024013133A MX 2024013133 A MX2024013133 A MX 2024013133A
Authority
MX
Mexico
Prior art keywords
composition
choroid
myopia
prevent
administering
Prior art date
Application number
MX2024013133A
Other languages
English (en)
Spanish (es)
Inventor
Kazuo Tsubota
Toshihide Kurihara
Shinichi Ikeda
Jing Hou
Original Assignee
Tsubota Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsubota Lab Inc filed Critical Tsubota Lab Inc
Publication of MX2024013133A publication Critical patent/MX2024013133A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024013133A 2022-04-26 2024-10-24 Metodo y composicion para prevenir o tratar la miopia MX2024013133A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022072596 2022-04-26
PCT/JP2023/016344 WO2023210657A1 (ja) 2022-04-26 2023-04-25 近視を予防または治療するための方法および組成物

Publications (1)

Publication Number Publication Date
MX2024013133A true MX2024013133A (es) 2024-12-06

Family

ID=88519036

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013133A MX2024013133A (es) 2022-04-26 2024-10-24 Metodo y composicion para prevenir o tratar la miopia

Country Status (9)

Country Link
EP (1) EP4516305A4 (https=)
JP (3) JP7713267B2 (https=)
KR (1) KR20250006145A (https=)
CN (1) CN119072322A (https=)
AU (1) AU2023258808A1 (https=)
CA (1) CA3249939A1 (https=)
MX (1) MX2024013133A (https=)
TW (1) TW202400198A (https=)
WO (1) WO2023210657A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025089394A1 (ja) * 2023-10-25 2025-05-01 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
JP7781461B2 (ja) 2023-10-25 2025-12-08 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
WO2025192737A1 (ja) * 2024-03-15 2025-09-18 株式会社坪田ラボ 脈絡膜菲薄化抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
TWI658828B (zh) * 2014-10-31 2019-05-11 中國醫藥大學 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
JP6640803B2 (ja) * 2016-09-09 2020-02-05 キリンホールディングス株式会社 眼疲労の抑制又は改善用組成物
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
CN107372821A (zh) * 2017-07-25 2017-11-24 芜湖职业技术学院 护眼保健酸奶及其制备方法
CN116568314A (zh) * 2020-09-23 2023-08-08 Pbl生物实验室 新型乳酸菌及其用途
JP7394737B2 (ja) 2020-10-30 2023-12-08 愛三工業株式会社 燃料供給装置
CN112493318A (zh) * 2020-12-01 2021-03-16 河北三元食品有限公司 一种专用于三周岁以上儿童的全营养奶粉及其制备方法
CN113349257A (zh) * 2021-04-13 2021-09-07 石家庄君乐宝乳业有限公司 一种有益于视力保护的发酵乳及其制备方法

Also Published As

Publication number Publication date
JP7808901B2 (ja) 2026-01-30
KR20250006145A (ko) 2025-01-10
CN119072322A (zh) 2024-12-03
JPWO2023210657A1 (https=) 2023-11-02
JP2025129384A (ja) 2025-09-04
EP4516305A4 (en) 2026-04-08
WO2023210657A1 (ja) 2023-11-02
EP4516305A1 (en) 2025-03-05
CA3249939A1 (en) 2025-06-17
JP7713267B2 (ja) 2025-07-25
AU2023258808A1 (en) 2024-11-07
JP2026063064A (ja) 2026-04-10
TW202400198A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
MX2024013133A (es) Metodo y composicion para prevenir o tratar la miopia
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
JOP20240084A1 (ar) مركبات الكينولين كمثبطات لـ kras
BR112022024450A2 (pt) 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8
MX2025000380A (es) Metodos de tratamiento con farmacos del sustrato cyp3a4
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
CY1123726T1 (el) Φαρμακευτικη συνθεση για αγωγη καρκινου, περιεχοντας αλας γαλακτικου μεταλλου
EP3530124A4 (en) DIET CONTAINING A SUBTILUS BACILIUS STRAIN, BACILIUS PUMILUS STRAIN AND BACILIUS LICHENFORMIS STRAIN AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ACUTE HEPATOPANCREATIC NECROSIS DISEASE OR BLANCHANCHESIS SYNDROME
BR112022014435A2 (pt) Composição herbicida líquida e métodos para aumentar a atividade herbicida de composições herbicidas líquidas e para tratar o material de propagação de plantas
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
WO2023147297A3 (en) Combination therapy for treating abnormal cell growth
MX2024014317A (es) Tratamientos con nirogacestat
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
BR112022024999A2 (pt) Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo
CO2022008737A2 (es) Método para el tratamiento de cáncer utilizando célula adyuvante artificial (aavc)
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
BR112022002692A2 (pt) Agentes antimaláricos
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
MX2023003357A (es) Composicion y metodo para la prevencion y el tratamiento de lesiones cutaneas por radiacion.
JOP20250276A1 (ar) مثبطات masp-2 و masp-3 وتركيبات وطرق مرتبطة بها لمعالجة مرض الخلية المنجلية
WO2020092117A3 (en) Killing senescent cells and treating senescence-associated conditions using a bel inhibitor and an mcl-1 inhibitor
JOP20250024A1 (ar) مثبطات il-15 نافعة لمعالجة التهاب الجلد التأتبي
WO2020016655A3 (en) Treatment of neuropathy with dna constructs expressing igf-1 isoforms
MX2022010725A (es) Una composicion efectiva para el cuidado personal anti-acne.